218 related articles for article (PubMed ID: 31438839)
1. Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury.
Tani T; Okamoto K; Fujiwara M; Katayama A; Tsuruoka S
Mol Med; 2019 Aug; 25(1):40. PubMed ID: 31438839
[TBL] [Abstract][Full Text] [Related]
2. Disruption of xanthine oxidoreductase gene attenuates renal ischemia reperfusion injury in mice.
Haga Y; Ohtsubo T; Murakami N; Noguchi H; Kansui Y; Goto K; Matsumura K; Kitazono T
Life Sci; 2017 Aug; 182():73-79. PubMed ID: 28625358
[TBL] [Abstract][Full Text] [Related]
3. Nitrite-derived nitric oxide by xanthine oxidoreductase protects the liver against ischemia-reperfusion injury.
Lu P; Liu F; Yao Z; Wang CY; Chen DD; Tian Y; Zhang JH; Wu YH
Hepatobiliary Pancreat Dis Int; 2005 Aug; 4(3):350-5. PubMed ID: 16109514
[TBL] [Abstract][Full Text] [Related]
4. Xanthine oxidoreductase and its inhibitors: relevance for gout.
Day RO; Kamel B; Kannangara DR; Williams KM; Graham GG
Clin Sci (Lond); 2016 Dec; 130(23):2167-2180. PubMed ID: 27798228
[TBL] [Abstract][Full Text] [Related]
5. Effects of topiroxostat and febuxostat on urinary albumin excretion and plasma xanthine oxidoreductase activity in db/db mice.
Nakamura T; Murase T; Nampei M; Morimoto N; Ashizawa N; Iwanaga T; Sakamoto R
Eur J Pharmacol; 2016 Jun; 780():224-31. PubMed ID: 27038523
[TBL] [Abstract][Full Text] [Related]
6. New Strategy That Delays Progression of Amyotrophic Lateral Sclerosis in G1H-G93A Transgenic Mice: Oral Administration of Xanthine Oxidoreductase Inhibitors That Are Not Substrates for the Purine Salvage Pathway.
Kato S; Kato M; Kusano T; Nishino T
J Neuropathol Exp Neurol; 2016 Dec; 75(12):1124-1144. PubMed ID: 27815397
[TBL] [Abstract][Full Text] [Related]
7. Renoprotective effect of the xanthine oxidoreductase inhibitor Topiroxostat under decreased angiotensin II type 1
Ohata K; Kamijo-Ikemori A; Sugaya T; Hibi C; Nakamura T; Murase T; Oikawa T; Hoshino S; Katayama K; Asano J; Kimura K; Shibagaki Y
Eur J Pharmacol; 2017 Nov; 815():88-97. PubMed ID: 28888756
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of neuronal protective effects of xanthine oxidoreductase inhibitors on severe whole-brain ischemia in mouse model and analysis of xanthine oxidoreductase activity in the mouse brain.
Suzuki G; Okamoto K; Kusano T; Matsuda Y; Fuse A; Yokota H
Neurol Med Chir (Tokyo); 2015; 55(1):77-85. PubMed ID: 25744353
[TBL] [Abstract][Full Text] [Related]
9. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity.
Furuhashi M
Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E827-E834. PubMed ID: 32893671
[TBL] [Abstract][Full Text] [Related]
10. Hyperuricemia-Related Diseases and Xanthine Oxidoreductase (XOR) Inhibitors: An Overview.
Chen C; Lü JM; Yao Q
Med Sci Monit; 2016 Jul; 22():2501-12. PubMed ID: 27423335
[TBL] [Abstract][Full Text] [Related]
11. Xanthine oxidoreductase: a journey from purine metabolism to cardiovascular excitation-contraction coupling.
Agarwal A; Banerjee A; Banerjee UC
Crit Rev Biotechnol; 2011 Sep; 31(3):264-80. PubMed ID: 21774633
[TBL] [Abstract][Full Text] [Related]
12. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
13. Effect of trimetazidine on xanthine oxidoreductase expression in rat kidney with ischemia--reperfusion injury.
Sulikowski T; Domanski L; Ciechanowski K; Adler G; Pawlik A; Safranow K; Dziedziejko V; Chlubek D; Ciechanowicz A
Arch Med Res; 2008 May; 39(4):459-62. PubMed ID: 18375259
[TBL] [Abstract][Full Text] [Related]
14. Nitrite-derived nitric oxide protects the rat kidney against ischemia/reperfusion injury in vivo: role for xanthine oxidoreductase.
Tripatara P; Patel NS; Webb A; Rathod K; Lecomte FM; Mazzon E; Cuzzocrea S; Yaqoob MM; Ahluwalia A; Thiemermann C
J Am Soc Nephrol; 2007 Feb; 18(2):570-80. PubMed ID: 17202421
[TBL] [Abstract][Full Text] [Related]
15. Perfecting a high hypoxanthine phosphoribosyltransferase activity-uricase KO mice to test the effects of purine- and non-purine-type xanthine dehydrogenase (XDH) inhibitors.
Hosoya T; Uchida S; Shibata S; Tomioka NH; Hosoyamada M
Br J Pharmacol; 2020 May; 177(10):2274-2285. PubMed ID: 31971609
[TBL] [Abstract][Full Text] [Related]
16. Protective Effects of Topiroxostat on an Ischemia-Reperfusion Model of Rat Hearts.
Tanno S; Yamamoto K; Kurata Y; Adachi M; Inoue Y; Otani N; Mishima M; Yamamoto Y; Kuwabara M; Ogino K; Miake J; Ninomiya H; Shirayoshi Y; Okada F; Yamamoto K; Hisatome I
Circ J; 2018 Mar; 82(4):1101-1111. PubMed ID: 29491325
[TBL] [Abstract][Full Text] [Related]
17. Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules.
Ohtsubo T; Matsumura K; Sakagami K; Fujii K; Tsuruya K; Noguchi H; Rovira II; Finkel T; Iida M
Hypertension; 2009 Oct; 54(4):868-76. PubMed ID: 19667249
[TBL] [Abstract][Full Text] [Related]
18. Reduction of nitrosative stress by methane: Neuroprotection through xanthine oxidoreductase inhibition in a rat model of mesenteric ischemia-reperfusion.
Poles MZ; Bódi N; Bagyánszki M; Fekete É; Mészáros AT; Varga G; Szűcs S; Nászai A; Kiss L; Kozlov AV; Boros M; Kaszaki J
Free Radic Biol Med; 2018 May; 120():160-169. PubMed ID: 29550332
[TBL] [Abstract][Full Text] [Related]
19. Increased kidney xanthine oxidoreductase activity in salt-induced experimental hypertension.
Laakso J; Mervaala E; Himberg JJ; Teräväinen TL; Karppanen H; Vapaatalo H; Lapatto R
Hypertension; 1998 Nov; 32(5):902-6. PubMed ID: 9822451
[TBL] [Abstract][Full Text] [Related]
20. Allopurinol, an inhibitor of purine catabolism, enhances susceptibility of tobacco to Tobacco mosaic virus.
Silvestri S; Murphy AM; Buonaurio R; Carr JP
Virus Res; 2008 Nov; 137(2):257-60. PubMed ID: 18675860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
